HERON THERAPEUTICS, INC. /DE/

SEC insider activity covers quarterly filings through June 30, 2026. Later filings are not included. Reported roles do not establish current employment or current holdings. SEC filing documents, sections and filing-text search cover filings dated January 1, 2000 onward. Earlier filings are deferred until after launch.

HRTX

organization

SIC: 2834

SEC Insider

$294.5M

968 transactions

Summary

HERON THERAPEUTICS, INC. /DE/ (HRTX) is an organization.

Recent Insider Transactions

As filed, including amendments; not net cash flow or current holdings. Joint reports count once. Totals cover known values only.

Buys: $120.4MSales: $126.0M51 insiders

Date	Insider	Type	Value
2026-06-16	Duarte Ira(EVP, Chief Financial Officer)	F	$1K
2026-06-16	Duarte Ira(EVP, Chief Financial Officer)	M	$0
2026-06-16	Duarte Ira(EVP, Chief Financial Officer)	M	—
2026-06-06	Forbes William P(EVP, Chief Development Officer)	M	$0
2026-06-06	Forbes William P(EVP, Chief Development Officer)	M	—
2026-05-06	Hensley Mark Earl(Chief Operating Officer)	M	$0
2026-05-06	Hensley Mark Earl(Chief Operating Officer)	M	—
2026-04-30	Collard Craig A(Chief Executive Officer)	M	$0
2026-04-30	Collard Craig A(Chief Executive Officer)	M	$0
2026-04-30	Collard Craig A(Chief Executive Officer)	M	—
2026-04-30	Collard Craig A(Chief Executive Officer)	M	—
2026-04-30	Duarte Ira(EVP, Chief Financial Officer)	M	$0
2026-04-30	Duarte Ira(EVP, Chief Financial Officer)	M	$0
2026-04-30	Duarte Ira(EVP, Chief Financial Officer)	M	—
2026-04-30	Duarte Ira(EVP, Chief Financial Officer)	M	—
2026-04-30	Forbes William P(EVP, Chief Development Officer)	M	$0
2026-04-30	Forbes William P(EVP, Chief Development Officer)	M	$0
2026-04-30	Forbes William P(EVP, Chief Development Officer)	M	—
2026-04-30	Forbes William P(EVP, Chief Development Officer)	M	—
2026-04-30	Hensley Mark Earl(Chief Operating Officer)	M	$0

SEC filings: SEC EDGAR

Activity data: SEC EDGAR

HERON THERAPEUTICS, INC. /DE/ — Contributions, Lobbying & Contracts | Poliscope